Detalles de la búsqueda
1.
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
Blood
; 139(5): 678-685, 2022 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861036
2.
A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
Cancer
; 129(24): 3905-3914, 2023 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37572086
3.
A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.
Hematol Oncol
; 41(5): 838-847, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37403752
4.
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Future Oncol
; 2023 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36617990
5.
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Haematologica
; 107(3): 625-634, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34320789
6.
Consolidation Treatment for Primary Central Nervous System Lymphoma: Which Modality for Whom?
Acta Haematol
; 144(4): 389-402, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33242855
7.
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Am J Hematol
; 95(6): 604-611, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32096887
8.
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Hematol Oncol
; 37(2): 185-192, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30756414
9.
Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
Am J Hematol
; 94(9): 992-1001, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31211434
10.
Primary CNS Lymphoma in the Elderly: The Challenge.
Acta Haematol
; 141(3): 138-145, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30783026
11.
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
Proc Natl Acad Sci U S A
; 113(1): E16-22, 2016 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26699502
12.
The Utility of 18F-fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography in Cutaneous B-Cell Lymphoma.
Isr Med Assoc J
; 21(9): 580-584, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31542900
13.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
N Engl J Med
; 373(25): 2425-37, 2015 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26639149
14.
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Haematologica
; 103(9): 1502-1510, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880603
15.
Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.
Hematol Oncol
; 36(1): 128-135, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28639416
16.
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Eur J Haematol
; 101(3): 399-406, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29949186
17.
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Am J Hematol
; 93(11): 1402-1410, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30129285
18.
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Am J Hematol
; 98(2): E24-E27, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36349541
19.
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Br J Haematol
; 178(5): 709-718, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28589704
20.
18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.
Isr Med Assoc J
; 19(6): 372-377, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28647936